chefbean
2021-10-27
Hee
Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":855982746,"tweetId":"855982746","gmtCreate":1635324859616,"gmtModify":1635324859616,"author":{"id":3554935180693279,"idStr":"3554935180693279","authorId":3554935180693279,"authorIdStr":"3554935180693279","name":"chefbean","avatar":"https://static.tigerbbs.com/75bcdd1d22221ef3b8f10c64b73ea420","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hee</p></body></html>","htmlText":"<html><head></head><body><p>Hee</p></body></html>","text":"Hee","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/855982746","repostId":1137943402,"repostType":4,"repost":{"id":"1137943402","kind":"news","pubTimestamp":1635324699,"share":"https://www.laohu8.com/m/news/1137943402?lang=&edition=full","pubTime":"2021-10-27 16:51","market":"us","language":"en","title":"Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1137943402","media":"seekingalpha","summary":"ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from A","content":"<ul>\n <li>ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.</li>\n <li>The difference in estimated glomerular filtration rate (eGFR) between the candidate and placebo was not statistically significant.</li>\n <li>An analysis of only those who completed the trial showed that that those in the ANG-3777 arm had a 12-month eGFR of 57.1mL/min/1.73m2 versus 52.2mL/min/1.73m2 for placebo. The company said this is \"potentially indicative of biologic activity.\"</li>\n <li>Angion said it had $100M in cash as of Sept. 30.</li>\n <li>In June, Angionabandoned pursuing ANG-3777 as a COVID-19 therapy.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-27 16:51 GMT+8 <a href=https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.\n...</p>\n\n<a href=\"https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1137943402","content_text":"ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.\nThe difference in estimated glomerular filtration rate (eGFR) between the candidate and placebo was not statistically significant.\nAn analysis of only those who completed the trial showed that that those in the ANG-3777 arm had a 12-month eGFR of 57.1mL/min/1.73m2 versus 52.2mL/min/1.73m2 for placebo. The company said this is \"potentially indicative of biologic activity.\"\nAngion said it had $100M in cash as of Sept. 30.\nIn June, Angionabandoned pursuing ANG-3777 as a COVID-19 therapy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":750,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/855982746"}
精彩评论